ATE482712T1 - Überstände von mesenchymstammzellen zur vorbeugung und behandlung von immunantworten in transplantationen - Google Patents

Überstände von mesenchymstammzellen zur vorbeugung und behandlung von immunantworten in transplantationen

Info

Publication number
ATE482712T1
ATE482712T1 AT00974007T AT00974007T ATE482712T1 AT E482712 T1 ATE482712 T1 AT E482712T1 AT 00974007 T AT00974007 T AT 00974007T AT 00974007 T AT00974007 T AT 00974007T AT E482712 T1 ATE482712 T1 AT E482712T1
Authority
AT
Austria
Prior art keywords
mesenchymal stem
immune response
transplantations
preventing
stem cell
Prior art date
Application number
AT00974007T
Other languages
English (en)
Inventor
Kevin Mcintosh
Joseph Mosca
Elena Klyushenkova
Original Assignee
Osiris Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osiris Therapeutics Inc filed Critical Osiris Therapeutics Inc
Application granted granted Critical
Publication of ATE482712T1 publication Critical patent/ATE482712T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00974007T 1999-10-26 2000-10-26 Überstände von mesenchymstammzellen zur vorbeugung und behandlung von immunantworten in transplantationen ATE482712T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/427,333 US6368636B1 (en) 1998-03-18 1999-10-26 Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
PCT/US2000/029815 WO2001032189A1 (en) 1999-10-26 2000-10-26 Supernatant from mesenchymal stem cells for prevention and treatment of immune responses in transplantation

Publications (1)

Publication Number Publication Date
ATE482712T1 true ATE482712T1 (de) 2010-10-15

Family

ID=23694416

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00974007T ATE482712T1 (de) 1999-10-26 2000-10-26 Überstände von mesenchymstammzellen zur vorbeugung und behandlung von immunantworten in transplantationen

Country Status (10)

Country Link
US (2) US6368636B1 (de)
EP (2) EP2269616A3 (de)
JP (1) JP2004506598A (de)
AT (1) ATE482712T1 (de)
AU (1) AU782064B2 (de)
CA (1) CA2387542C (de)
DE (1) DE60045034D1 (de)
ES (1) ES2351203T3 (de)
PT (1) PT1223956E (de)
WO (1) WO2001032189A1 (de)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU749675B2 (en) * 1998-03-13 2002-07-04 Mesoblast International Sarl Uses for human non-autologous mesenchymal stem cells
US20040265285A1 (en) * 1999-04-15 2004-12-30 Monash University Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US20050042679A1 (en) * 1999-04-15 2005-02-24 Monash University Diagnostic indicator of thymic function
AU2003901668A0 (en) * 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
AUPQ147799A0 (en) * 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
US20050158289A1 (en) * 1999-07-07 2005-07-21 Simmons Paul J. Mesenchymal precursor cell and use thereof in the repair of bone defects and fractures in mammals
US8062675B2 (en) 1999-07-07 2011-11-22 Angioblast Systems, Inc. Mesenchymal precursor cell
US7670628B2 (en) * 1999-07-07 2010-03-02 Angioblast Systems, Inc. Mesenchymal precursor cell
US8147824B2 (en) 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
AU2001253400B2 (en) * 2000-04-11 2007-03-01 University Of Southern California A method to prevent graft rejection using tgf-beta to induce t suppressor cells
US20060088512A1 (en) * 2001-10-15 2006-04-27 Monash University Treatment of T cell disorders
IL155728A0 (en) * 2000-11-22 2003-11-23 Geron Corp Tolerizing allografts of pluripotent stem cells
US7311905B2 (en) * 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
DK1349918T3 (da) * 2000-12-06 2014-11-10 Anthrogenesis Corp Fremgangsmåde til indsamling af stamceller fra moderkagen
US20080152629A1 (en) * 2000-12-06 2008-06-26 James Edinger Placental stem cell populations
EP2316919B1 (de) * 2001-02-14 2015-10-07 Anthrogenesis Corporation Post-partum Säugetier-Plazenta, deren Verwendung und daraus gewonnene Stammzellen
EP3246396B1 (de) * 2001-02-14 2020-01-29 Celularity, Inc. Regeneration und repopulation von dezellularisierten geweben und kadaverorganen durch stammzellen
WO2003024462A1 (en) * 2001-09-19 2003-03-27 Henry Ford Health System Cardiac transplantation of stem cells for the treatment of heart failure
JP2005531507A (ja) * 2002-03-02 2005-10-20 ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ストローマ細胞前駆体による抗癌物質の局所的な産生および／または送達方法
US7462181B2 (en) * 2002-06-04 2008-12-09 Stanford Office Of Technology Licensing Device and method for rapid aspiration and collection of body tissue from within an enclosed body space
WO2004046312A2 (en) * 2002-11-15 2004-06-03 The Board Of Trustees Of The University Of Illinois Methods for in vitro expansion of hematopoietic stem cells
US20040101959A1 (en) * 2002-11-21 2004-05-27 Olga Marko Treatment of tissue with undifferentiated mesenchymal cells
WO2004047860A2 (de) * 2002-11-28 2004-06-10 Genethor Gmbh Nicht antigen präsentierende, mhc ii exprimierende zellen zur unterdrückung von pathologischen immunreaktionen
EP1608411B1 (de) * 2003-04-01 2010-09-29 United States Government as represented by the Department of Veteran's Affaires Auf stammzellen, vorläuferzellen oder targetzellen basierende behandlung von multiorganversagen.
GB0321337D0 (en) * 2003-09-11 2003-10-15 Massone Mobile Advertising Sys Method and system for distributing advertisements
US20080279812A1 (en) * 2003-12-05 2008-11-13 Norwood Immunology, Ltd. Disease Prevention and Vaccination Prior to Thymic Reactivation
TR201901268T4 (tr) * 2004-03-22 2019-02-21 Mesoblast Int Sarl Mezenkimal kök hücreleri ve bunların kullanımları.
EP3461884B1 (de) 2004-03-22 2025-05-28 Mesoblast International Sàrl Mesenchymale stammzellen und verwendungen davon
US7670596B2 (en) * 2004-04-23 2010-03-02 Bioe, Inc. Multi-lineage progenitor cells
US7622108B2 (en) * 2004-04-23 2009-11-24 Bioe, Inc. Multi-lineage progenitor cells
JP2007536936A (ja) * 2004-05-14 2007-12-20 ベクトン・ディキンソン・アンド・カンパニー 幹細胞集団および使用方法
CA2504451A1 (en) * 2004-08-10 2006-02-10 Geron Corporation Dendritic cell vaccines for treating cancer made from embryonic stem cells
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
DK1799236T3 (da) * 2004-09-10 2012-09-03 Cognate Therapeutics Inc Leverstromaceller til forebyggelse og behandling af immunresponser ved transplantation
KR20070085288A (ko) 2004-09-24 2007-08-27 안지오블라스트 시스템스 인코퍼레이티드 간엽 전구세포의 증식 및/또는 생존성 증강 방법
CA2512667A1 (en) * 2005-01-07 2006-07-07 Takahiro Ochiya Human hepatocyte-like cells and uses thereof
CN101137292A (zh) * 2005-01-11 2008-03-05 同源治疗公司 用于移植的神经干细胞的免疫保护的骨髓基质细胞
CA2608048A1 (en) * 2005-05-10 2006-11-16 United States Of America Department Of Veteran's Affairs Therapy of kidney diseases and multiorgan failure with mesenchymal stem cells and mesenchymal stem cell conditioned media
WO2008020815A1 (en) * 2006-08-15 2008-02-21 Agency For Science, Technology And Research Mesenchymal stem cell conditioned medium
KR101536239B1 (ko) * 2005-09-23 2015-07-13 셀레릭스, 에스.엘. 면역조절활성을 갖는 세포 개체군, 분리 방법 및 용도
US20070082328A1 (en) * 2005-09-27 2007-04-12 Donnie Rudd Rotatable time varying electromagnetic force bioreactor and method of using the same
DK1957633T3 (en) 2005-10-13 2014-03-17 Anthrogenesis Corp Immunomodulation USING PLACE SPEECH STEM CELLS
US10117900B2 (en) 2005-11-09 2018-11-06 Athersys, Inc. MAPC treatment of brain injuries and diseases
US11000546B2 (en) 2005-11-09 2021-05-11 Athersys, Inc. Immunomodulatory properties of MAPCs and uses thereof
PT2471904T (pt) * 2005-12-29 2019-02-25 Celularity Inc População de células estaminais placentárias
CN101389754A (zh) 2005-12-29 2009-03-18 人类起源公司 胎盘干细胞和第二来源干细胞的联合培养
US20070258963A1 (en) 2006-01-13 2007-11-08 Osiris Therapeutics, Inc. Mesenchymal stem cells expressing TNF-alpha receptors
CN104027359A (zh) 2006-01-23 2014-09-10 阿特西斯公司 无附加的免疫抑制治疗的mapc治疗法
CA2646491A1 (en) * 2006-04-17 2007-10-25 Bioe, Inc. Differentiation of multi-lineage progenitor cells to respiratory epithelial cells
HUE059011T2 (hu) * 2006-05-31 2022-09-28 Childrens Medical Center Immunmodulátorként szolgáló ABC5-pozitív mezenchimális õssejtek
CN101501185A (zh) * 2006-06-09 2009-08-05 人类起源公司 胎盘巢(placental niche)及其培养干细胞的用途
US7993918B2 (en) * 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
CA2913024A1 (en) 2006-11-03 2008-05-08 Aastrom Biosciences, Inc. Mixed cell populations for tissue repair and separation technique for cell processing
EP3763376A1 (de) * 2007-02-12 2021-01-13 Celularity, Inc. Behandlung von infektionskrankheiten mithilfe von plazenta-stammzellen
EP2607477B1 (de) 2007-05-03 2020-09-23 The Brigham and Women's Hospital, Inc. Multipotente stammzellen und ihre verwendung
TWM322542U (en) * 2007-05-23 2007-11-21 Universal Scient Ind Co Ltd Testing machine
EP2171043B1 (de) * 2007-06-15 2015-03-18 Garnet BioTherapeutics, Inc Behandlung von krankheiten und störungen unter verwendung in vitro kultivierter und expandierter selbsterneuernder koloniebildender zellen
CA2693827A1 (en) * 2007-07-25 2009-01-29 Bioe, Inc. Differentiation of multi-lineage progenitor cells to chondrocytes
NZ599825A (en) 2007-09-28 2014-10-31 Anthrogenesis Corp Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
DK2205721T3 (en) 2007-10-17 2016-10-24 Txcell TR1 cells mesenchymal stem cells and uses thereof
US9011840B2 (en) * 2008-03-14 2015-04-21 The Board Of Trustees Of The University Of Illinois Activated mesenchymal stem cells for wound healing and impaired tissue regeneration
US20110044958A1 (en) * 2008-03-14 2011-02-24 The Board Of Trustees Of The University Of Illinois Activated mesenchymal stem cells for the prevention and repair of inflammatory states
EP2279246A4 (de) * 2008-05-02 2012-03-28 Massachusetts Inst Technology Verfahren und zusammensetzungen zur modulation immunologischer toleranz
CA2724839A1 (en) * 2008-05-21 2009-11-26 Bioe Llc Differentiation of multi-lineage progenitor cells to pancreatic cells
KR20240052847A (ko) 2008-08-20 2024-04-23 셀룰래리티 인코포레이티드 개선된 세포 조성물 및 그의 제조 방법
WO2010021715A1 (en) * 2008-08-20 2010-02-25 Anthrogenesis Corporation Treatment of stroke using isolated placental cells
CA2734446C (en) 2008-08-22 2017-06-20 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
PT3130923T (pt) 2008-11-14 2020-06-17 Brigham & Womens Hospital Inc Métodos terapêuticos relacionados com células estaminais
US11542328B2 (en) 2008-11-14 2023-01-03 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
AU2009316541B2 (en) * 2008-11-19 2015-08-06 Celularity Inc. Amnion derived adherent cells
NZ592839A (en) * 2008-11-21 2012-10-26 Anthrogenesis Corp Treatment of diseases, disorders or conditions of the lung using placental cells
US9301975B2 (en) 2009-05-01 2016-04-05 Biocardia, Inc. Method of preparing autologous cells and method of use for therapy
WO2011011500A1 (en) * 2009-07-21 2011-01-27 Abt Holding Company Use of stem cells to reduce leukocyte extravasation
DK3284818T3 (da) * 2010-01-26 2022-06-20 Celularity Inc Behandling af knoglerelateret kræft ved hjælp af placenta stamceller
LT2556145T (lt) 2010-04-07 2016-11-10 Anthrogenesis Corporation Angiogenezė naudojant placentos kamienines ląsteles
MX2012011543A (es) 2010-04-08 2013-05-06 Anthrogenesis Corp Tratamiento de sarcoidosis empleando celulas madre placentarias.
KR101203954B1 (ko) 2010-04-15 2012-11-22 서울대학교산학협력단 혈관 내피 세포성 중간엽 줄기세포를 포함하는 면역 조절용 조성물
SG185526A1 (en) 2010-05-12 2012-12-28 Abt Holding Co Modulation of splenocytes in cell therapy
ES2666746T3 (es) 2010-07-13 2018-05-07 Anthrogenesis Corporation Métodos para generar linfocitos citolíticos naturales
WO2012048276A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
US20120087868A1 (en) 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
JP6104896B2 (ja) 2011-06-01 2017-03-29 アントフロゲネシス コーポレーション 胎盤幹細胞を使用する疼痛の治療
WO2013055476A1 (en) 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
US20150283180A1 (en) * 2011-11-04 2015-10-08 The Texas A& M University System Prevention and Treatment of Transplant Rejection with Mesenchymal Stem Cells and/or TSG-6 Protein
CN115137753A (zh) 2013-02-05 2022-10-04 细胞结构公司 来自胎盘的自然杀伤细胞
AU2014219026B2 (en) 2013-02-19 2018-11-29 Children's Medical Center Corporation ABCB5(+) stem cells for treating ocular disease
IL289870B2 (en) 2013-04-12 2023-03-01 Lafrancesca Saverio Improving organs for transplantation
EP4008369A1 (de) 2013-05-10 2022-06-08 Children's Medical Center Corporation Wundheilung und gewebeaufbau
EP4218779B1 (de) * 2013-05-22 2026-04-22 National Center Of Neurology And Psychiatry Mesenchymale stammzellen und immunogene zur verwendung bei der induktion einer erworbenen immunologischen toleranz
KR101723265B1 (ko) 2013-08-16 2017-04-04 가톨릭대학교 산학협력단 mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
WO2015023147A1 (ko) * 2013-08-16 2015-02-19 가톨릭대학교 산학협력단 mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽 줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
WO2015073913A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
EP3198006B1 (de) 2014-09-26 2021-03-24 Terumo BCT, Inc. Geplante fütterung
RU2644650C2 (ru) 2014-12-01 2018-02-13 Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" Материал стволовых клеток и способ его получения
WO2016109824A1 (en) * 2014-12-31 2016-07-07 Applied Biologics, Llc Reconstituted amniotic membrane-amniotic fluid combination tissue graft with standardized stem cell component
WO2016170541A1 (en) * 2015-04-21 2016-10-27 Enlivex Therapeutics Ltd. Therapeutic pooled blood apoptotic cell preparations and uses thereof
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
EP4628116A3 (de) 2016-02-01 2025-12-10 Regenmed Systems, Inc. Systeme und verfahren zur schätzung der authentizität eines lokalen netzwerks einer vorrichtung zur initiierung einer ferntransaktion
GB201604304D0 (en) 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
RU2708329C2 (ru) 2016-05-31 2019-12-05 Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" Материал стволовых клеток, композиции и способы применения
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
CN117247899A (zh) 2017-03-31 2023-12-19 泰尔茂比司特公司 细胞扩增
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
WO2018227363A1 (zh) * 2017-06-13 2018-12-20 广州赛莱拉干细胞科技股份有限公司 一种防治糖尿病足的干细胞组合物及其应用、干细胞制剂
SG11202004680UA (en) 2017-11-22 2020-06-29 Mesoblast Int Sarl Cellular compositions and methods of treatment i
WO2019210109A1 (en) 2018-04-25 2019-10-31 Children's Medical Center Corporation Abcb5 ligands and substrates
EP4314244B1 (de) 2021-03-23 2025-07-23 Terumo BCT, Inc. Zellerfassung und -erweiterung
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
PT118103A (pt) 2022-07-13 2024-01-15 Univ Aveiro Biomaterial para imunomodulação, processo de produção e suas aplicações
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733542A (en) * 1990-11-16 1998-03-31 Haynesworth; Stephen E. Enhancing bone marrow engraftment using MSCS
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5591625A (en) 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
PT1066060E (pt) * 1998-04-03 2003-12-31 Osiris Therapeutics Inc Celulas estaminais mesenquimais como imunossupressores
US6685936B2 (en) * 1999-10-12 2004-02-03 Osiris Therapeutics, Inc. Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation
CA2490682A1 (en) 2004-12-16 2006-06-16 Ibm Canada Limited - Ibm Canada Limitee Method and system for advanced downloadings of urls for web navigation
TW200819387A (en) 2006-10-19 2008-05-01 Univ Yuan Ze Micro-reacting device having a micro-channel flow-guiding block

Also Published As

Publication number Publication date
CA2387542A1 (en) 2001-05-10
WO2001032189A9 (en) 2002-07-04
PT1223956E (pt) 2010-12-06
WO2001032189A1 (en) 2001-05-10
US20020085996A1 (en) 2002-07-04
EP1223956A1 (de) 2002-07-24
EP2269616A3 (de) 2012-06-27
EP2269616A2 (de) 2011-01-05
EP1223956B1 (de) 2010-09-29
DE60045034D1 (de) 2010-11-11
JP2004506598A (ja) 2004-03-04
US6875430B2 (en) 2005-04-05
ES2351203T3 (es) 2011-02-01
US6368636B1 (en) 2002-04-09
CA2387542C (en) 2012-01-24
AU1244501A (en) 2001-05-14
AU782064B2 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
ATE482712T1 (de) Überstände von mesenchymstammzellen zur vorbeugung und behandlung von immunantworten in transplantationen
ATE319312T1 (de) Suppressorzellen zur prävention und behandlung von immunantworten bei transplantationen
ATE316795T1 (de) Mesenchymale stammzellen für die prävention und behandlung von immunantworten bei transplantationen
ES2180653T3 (es) Tratamiento de material biologico antes de la implantacion.
DK0987998T3 (da) Decellulering af væv
DE69837491D1 (de) Menschliche mesenchymale stammzellen aus peripherem blut
ATE265191T1 (de) Herstellungsverfahren von gewebe zur implantation
DE69941903D1 (de) Behandlung von patienten die eine knochenmarktransplantation oder eine transplantation peripherer blutstammzellen erhalten mit anti-cd20 antikörpern
NO963742L (no) Fremgangsmåte til å stimulere hematopoese med hemaglobin
DE69525151D1 (de) Methoden zur krankheitsbehandlung unter verwendung von sertoli-zellen und allotransplantat oder xenotransplantat
WO2007070301A3 (en) Vascular graft sterilization and decellularization
WO2004011631A3 (en) Methods and compositions for treating tissue defects using pulsed electromagnetic field stimulus
DE69829202D1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
DK1150698T3 (da) Anvendelser af vaskulær endotelvækstfaktor i behandlingen af erektil dysfunktion
ATE297217T1 (de) Zusammensetzung zur vorbeugung und behandlung von transplantatabstossung
BR0107544A (pt) Composição de promoção de secreção de bile
DE60033840D1 (de) Antisense-zusammensetzungen und verfahren zur behandlung von krebs
DE69937892D1 (de) Implantatmaterial
GB2400556B (en) Therapeutic composition for autoimmune conditions
NO20054912L (no) Behandling av aspergillus infeksjoner med tymosin alfa 1
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
SG158124A1 (en) Liver stromal cells for prevention and treatment of immune responses in transplantation
NO20022109D0 (no) Anvendelse av treosulfan for behandling av pasienter för benmargs- eller blodstamcelletansplantasjon
UA6151U (en) Method for treating experimental burns
UA69988A (en) Method for treating complicated choledocholithiasis

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties